As of 3:57pm ET
| -0.085 / -1.56%|
The 2 analysts offering 12-month price forecasts for ZIOPHARM Oncology Inc have a median target of 13.50, with a high estimate of 21.00 and a low estimate of 6.00. The median estimate represents a +151.16% increase from the last price of 5.38.
The current consensus among 5 polled investment analysts is to Hold stock in ZIOPHARM Oncology Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.